Adalvo is pleased to announce that the successful Pivotal BE Study for Cladribine Tablets 10mg has been completed. Committed to innovation and a proactive market strategy, we are working towards becoming among the first companies to file a generic in the EU.
Cladribine Tablets is used for the treatment of Multiple Sclerosis. In 2022, this product was sold at $1064M globally, with a 3Y CAGR of 18%, according to IQVIA.
The successful development of this product further highlights Adalvo's ability to offer difficult-to-make, high-value products to their partners.
As a company committed to their neurology portfolio, Adalvo offers an array of dossiers and aims to assist our partners in overcoming any challenges that may arise with these mature products.
Partner up now!
At Adalvo, there are no half measures – we arealways on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Reach out to your preferred Business Partner below to access Adalvo's CNS/Neurology dossiers.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
bruno.alves@adalvo.com - Brazil
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!